Trial
NCT03184558
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
BerGenBio ASA
Collaborators
Merck Sharp & Dohme LLC
Condition
Triple Negative Breast Cancer
Intervention
Bemcentinib
Why stopped
Based on planned futility assessment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09